Results 21 to 30 of about 27,136 (186)
The remarkable history of pneumococcal vaccination: an ongoing challenge
Pneumonia, 2022 Although it varies with age and geographical distribution, the global burden of infection with Streptococcus pneumoniae (pneumococcus) remains considerable.
Daniel M. Musher +2 more
doaj +1 more source
Эпидемиология и вакцинопрофилактика, 2023 Relevance. In 2007, WHO recommended pneumococcal conjugate vaccines (PCV) be included in national immunization schedules for young children. By 2020, 145 countries, including Russia, were using PCV. Aims.
N. N. Kostyukova, V. A. Bekhalo
doaj +1 more source
International Journal of Infectious Diseases, 2022 Objectives: Budgetary constraints force healthcare authorities to set priorities for optimal vaccine interventions. A comprehensive decision-making tool would help inform the best combination and sequence of introduction of vaccines within constrained ...
Chun-Yi Lu +4 more
doaj +1 more source
Indian Journal of Medical Microbiology, 2018 Streptococcus pneumoniae continues to take a heavy toll on childhood mortality and morbidity across the developing world. An estimated 10.6 million invasive pneumococcal diseases (IPDs) occur every year, with nearly 1 million deaths in children under 5 years of age. Introduction of vaccines in the childhood immunisation programme in developed world has
Anand, Manoharan, Ranjith, Jayaraman
openaire +2 more sources
Expert Review of VaccinesIntroduction There was no 13-valent pneumococcal conjugate vaccine (PCV13) adult antibody concentration threshold regulatory criterion for licensure – unlike the pediatric indication; consequently, for the adult indication, PCV13 serotype-specific ...
Mark A. Fletcher +5 more
doaj +1 more source
CLINICAL AND IMMUNOLOGICAL EFFECT OF PNEUMOCOCCAL CONJUGATED VACCINES IN IMMUNOCOMPROMISED PATIENTS
Педиатрическая фармакология, 2010 Invasive pneumococcal infection is the most frequent cause of death in patients with immunodeficiences. The antibiotics used previously for prevention purposes are not efficient enough due to the developing antibiotic resistance.
A.A. Tarasova, M.P. Kostinov
doaj +2 more sources
Using Synthetic Glycans to Investigate Anti‐Glycan Antibodies and Explore Their Medical Potential
Angewandte Chemie International Edition, EarlyView.Anti‐glycan antibodies are essential in health and disease. Access to novel glycan structures paves the way for progress in antibody profiling for biomarker discovery, antibody development, and vaccine design. We summarize the strategies to synthesize and utilize synthetic glycans for the development and application of anti‐glycan antibodies in basic ...
Fabienne Weber +4 more
wiley +1 more source
Next-Generation Whole-Cell Pneumococcal Vaccine
Vaccines, 2019 Streptococcus pneumoniae remains a major public health hazard. Although Pneumococcal Conjugate Vaccines (PCVs) are available and have significantly reduced the rate of invasive pneumococcal diseases, there is still a need for new vaccines with unlimited ...
Victor Morais +2 more
doaj +1 more source
Biotechnology Progress, EarlyView.Abstract Traditional off‐line analysis methods to quantify residual metabolite concentrations in a drug substance fermentation process consume valuable time, require costly resources, and demand potentially hazardous manual operations when working with pathogenic biological organisms.
Griffin P. Thomas +7 more
wiley +1 more source
ERA OF CONJUGATE VACCINES: INTERNATIONAL EXPERIENCE OF SUCCESSFUL APPLICATION
Педиатрическая фармакология, 2008 The article highlights comparative characteristics of the polysaccharide and conjugate vaccines against pneumococcal infection, meningococcosis and haemophilus influenza. The author stresses the advantage of the conjugate vaccines.
M.V. Fedoseenko +2 more
doaj +2 more sources